{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:33Z","timestamp":1786649913133,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of combining intravitreal dexamethasone implant (IVDI) and ranibizumab in patients with persistent diabetic macular edema (DME) who are unresponsive to multiple treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study included 36 eyes from 28 patients. Eligibility criteria were persistent DME with a central macular thickness (CMT) \u2265300 \u00b5m despite \u22653 consecutive monthly intravitreal anti-VEGF injections and\/or focal\/grid laser photocoagulation at least 6 weeks before enrolment. Patients with &lt;50% reduction in CMT or &lt;2-line improvement in best-corrected visual acuity (BCVA) after prior treatments were enrolled. All eyes received a single IVDI and were followed monthly for 6 months. If BCVA decreased by \u22655 ETDRS letters or CMT increased by \u2265100 \u00b5m, additional intravitreal ranibizumab (IVRB) was permitted. The primary outcomes were BCVA, intraocular pressure (IOP), and CMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The baseline mean BCVA was 0.65 \u00b1 0.30 logMAR, mean CMT 501.2 \u00b1 145.9 \u00b5m, and mean IOP 16.2 \u00b1 2.5 mmHg. BCVA improved significantly to 0.53 \u00b1 0.27 logMAR at month 1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), 0.46 \u00b1 0.27 at month 2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and 0.54 \u00b1 0.31 at month 3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014). Correspondingly, CMT decreased to 293.7 \u00b1 77.6 \u00b5m, 273.3 \u00b1 51.3 \u00b5m, and 351.0 \u00b1 112.3 \u00b5m (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). DME recurred in 16\u201317 eyes between months 3 and 5, requiring additional IVRB. Following retreatment, BCVA remained stable (0.50\u20130.54 logMAR,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.029) and CMT persisted between 353 and 382 \u00b5m (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.001) through month 6. IOP increased significantly during the first 2 months but returned to baseline thereafter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IVDI demonstrated substantial enhancement in patients with chronic persistent DME who were resistant to different treatments, with peak efficacy observed in the second month. Therefore, it may be considered an alternative therapeutic choice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_169_25","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:00:09Z","timestamp":1770112809000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-Term Results of Dexamethasone Intravitreal Implant in Patients with Persistent Diabetic Macular Edema"],"prefix":"10.4103","volume":"29","author":[{"given":"\u015e","family":"K\u0131l\u0131\u00e7","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Samsun Education and Research Hospital, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RG","family":"Seymeno\u011flu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kar\u015f\u0131yaka Ophthalmology Hospital, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Celal Bayar University Faculty of Medicine, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EF","family":"Ba\u015fer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kar\u015f\u0131yaka Ophthalmology Hospital, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jdi.13480","article-title":"Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy","volume":"12","author":"Lin","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"1077669","DOI":"10.3389\/fendo.2022.1077669","article-title":"Diabetic retinopathy: Looking forward to 2030","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.apjo.2024.100077","article-title":"Diabetic retinopathy","volume":"13","author":"Jonas","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"23981","DOI":"10.1038\/s41598-021-03433-2","article-title":"Analysis of cytokines in the aqueous humor during intravitreal Ranibizumab treatment of diabetic macular edema","volume":"11","author":"de Freitas","year":"2021","journal-title":"Sci Rep"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","article-title":"Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: What we have learned and what should we learn further?","volume":"22","author":"Uludag","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.survophthal.2021.03.001","article-title":"Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review","volume":"66","author":"Br Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14712598.2021.1928629","article-title":"Ranibizumab for the treatment of diabetic retinopathy","volume":"21","author":"Chatziralli","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"11766","DOI":"10.3390\/ijms241411766","article-title":"Esaxerenone \u0131nhibits renal angiogenesis and endothelial-mesenchymal transition via the VEGFA and TGF-\u03b21 pathways in aldosterone-\u0131nfused mice","volume":"24","author":"Gao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.3390\/ijms23147585","article-title":"The role of \u0131ntravitreal corticosteroids in the treatment of DME: Predictive OCT biomarkers","volume":"23","author":"Munk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.oret.2022.12.009","article-title":"A comparison of ocular complications after 0.7 mg dexamethasone implant versus 2 mg of \u0131ntravitreal triamcinolone in vitrectomized eyes","volume":"7","author":"Wakabayashi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/02713683.2023.2168013","article-title":"Intravitreal ranibizumab and dexamethasone implant \u0131njections as primary treatment of diabetic macular edema: The month 24 results from simultaneously double protocol","volume":"48","author":"Kaya","year":"2023","journal-title":"Curr Eye Res"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Diabetic retinopathy clinical research. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000336225","article-title":"Intravitreal dexamethasone implant in patients with persistent diabetic macular edema","volume":"228","author":"Zucchiatti","year":"2012","journal-title":"Ophthalmologica"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"364143","DOI":"10.1155\/2014\/364143","article-title":"Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant","volume":"2014","author":"Zalewski","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/eop.10.82","article-title":"Sustained-release dexamethasone intravitreal implant for treatment of diabetic macular edema","volume":"6","author":"Kuppermann","year":"2011","journal-title":"Expert Rev Ophthalmol"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00417-016-3472-1","article-title":"A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema","volume":"255","author":"Callanan","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2147\/OPTH.S79948","article-title":"Dexamethasone intravitreal implant in the treatment of diabetic macular edema","volume":"9","author":"Dugel","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1111\/aos.15724","article-title":"Anti-VEGF and steroid combination therapy relative to anti-VEGF mono therapy for the treatment of refractory DME: A systematic review of efficacy and meta-analysis of safety","volume":"102","author":"Hatamnejad","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"1219861","DOI":"10.3389\/fphar.2023.1219861","article-title":"Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex) in epiretinal membrane peeling surgery: A prospective randomized controlled trial","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S48364","article-title":"Preliminary results of an intravitreal dexamethasone implant (Ozurdex\u00ae) in patients with persistent diabetic macular edema","volume":"7","author":"Pacella","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-2999(97)01464-7","article-title":"Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells","volume":"341","author":"Nauck","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R24-20260420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","article-title":"Diabetic macular edema: Pathogenesis and treatment","volume":"54","author":"Bhagat","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-015-0148-2","article-title":"Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: Subgroup analysis of the MEAD study","volume":"15","author":"Augustin","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R26-20260420","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/ICU.0000000000000042","article-title":"Ultra-wide-field fluorescein angiography in retinal disease","volume":"25","author":"Patel","year":"2014","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_169_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:50Z","timestamp":1786647590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_169_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_169_25","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-03-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}